Anti-atherosclerotic effects of an improved apolipoprotein A-I mimetic peptide

Chapman, 2010, Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk, Pharmacol. Ther., 126, 314, 10.1016/j.pharmthera.2010.01.008 Carrera, 2012, Trends in risk factors, patterns and causes in hospitalized strokes over 25 years: the Lausanne Stroke Registry, Circulation, 125, 1979 Miura, 2019, Atherosclerotic coronary artery disease in patients with cardiometabolic syndrome, Cardiol. Res., 10, 69, 10.14740/cr857 Farbstein, 2012, HDL dysfunction in diabetes: causes and possible treatments, Expert. Rev. Cardiovasc. Ther., 10, 353, 10.1586/erc.11.182 Sviridov, 2008, Antiatherogenic functionality of high density lipoprotein: how much versus how good, J. Atheroscler. Thromb., 15, 52, 10.5551/jat.E571 Rohatgi, 2014, HDL cholesterol efflux capacity and incident cardiovascular events, N. Engl. J. Med., 371, 2383, 10.1056/NEJMoa1409065 Imaizumi, 2015, Association between cholesterol efflux capacity and coronary restenosis after successful stent implantation, Heart Vessel., 31, 1257, 10.1007/s00380-015-0738-1 Annema, 2016, HDL cholesterol efflux predicts graft failure in renal transplant recipients, J. Am. Soc. Nephrol., 27, 595, 10.1681/ASN.2014090857 Di Bartolo, 2018, Translating evidence of HDL and plaque regression, Arterioscler. Thromb. Vasc. Biol., 38, 1961, 10.1161/ATVBAHA.118.307026 Armitage, 2019, Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week, J. Am. Coll. Cardiol., 73, 477, 10.1016/j.jacc.2018.10.072 Iwata, 2011, Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits, Atherosclerosis., 218, 300, 10.1016/j.atherosclerosis.2011.05.029 Nissen, 2003, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial, JAMA, 290, 2292, 10.1001/jama.290.17.2292 Navab, 2002, Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol, Circulation., 105, 290, 10.1161/hc0302.103711 Li, 2004, Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice, Circulation., 110, 1701, 10.1161/01.CIR.0000142857.79401.69 Uehara, 2013, FAMP, a novel apoA-I mimetic peptide, suppresses aortic plaque formation through promotion of biological HDL function in ApoE-deficient mice, J. Am. Heart Assoc., 2, 10.1161/JAHA.113.000048 Shimizu, 2015, Newly developed apolipoprotein A-I mimetic peptide promotes macrophage reverse cholesterol transport in vivo, Int. J. Cardiol., 192, 82, 10.1016/j.ijcard.2015.05.012 Suematsu, 2016, A novel inducible cholesterol efflux peptide, FAMP, protects against myocardial ischemia reperfusion injury through a nitric oxide pathway, Int. J. Cardiol., 202, 810, 10.1016/j.ijcard.2015.10.013 Takata, 2016, The ApoA-I mimetic peptide FAMP promotes recovery from hindlimb ischemia through a nitric oxide (NO)-related pathway, Int. J. Cardiol., 207, 317, 10.1016/j.ijcard.2016.01.012 Ando, 2010, Structure-activity relationship of indolicidin, a Trp-rich antibacterial peptide, J. Pept. Sci., 16, 171, 10.1002/psc.1217 Uehara, 2008, POPC/apoA-I discs as a potent lipoprotein modulator in Tangier disease, Atherosclerosis., 197, 283, 10.1016/j.atherosclerosis.2007.04.025 Kido, 2001, Lipoprotein analysis using agarose gel electrophoresis and differential staining of lipids, J. Atheroscler. Thromb., 8, 7, 10.5551/jat1994.8.7 Tanigawa, 2007, Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport, Circulation., 116, 1267, 10.1161/CIRCULATIONAHA.107.704254 Alexander, 2009, Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano, Arterioscler. Thromb. Vasc. Biol., 29, 1496, 10.1161/ATVBAHA.109.191379 Xie, 2010, D-4F, an apolipoprotein A-Imimetic peptide, promotes cholesterol efflux from macrophages via ATP-binding cassette transporter A1, Tohoku J. Exp. Med., 220, 223, 10.1620/tjem.220.223 de la Llera-Moya, 2010, The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages, Arterioscler. Thromb. Vasc. Biol., 30, 796, 10.1161/ATVBAHA.109.199158 Buckley, 2018, Interleukin-1 blockade in cardiovascular diseases: a clinical update, Eur. Heart J., 39, 2063, 10.1093/eurheartj/ehy128 Ait-Oufella, 2019, Anticytokine immune therapy and atherothrombotic cardiovascular risk, Arterioscler. Thromb. Vasc. Biol., 39, 1510, 10.1161/ATVBAHA.119.311998 Ridker, 2017, Antiinflammatory therapy with canakinumab for atherosclerotic disease, N. Engl. J. Med., 377, 1119, 10.1056/NEJMoa1707914 Averill, 2014, The apolipoprotein-AI mimetic peptide L4F at a modest dose does not attenuate weight gain, inflammation, or atherosclerosis in LDLR-null mice, PLoS One, 9, 10.1371/journal.pone.0109252 Marino, 2012, ApoA-1 mimetic restores adiponectin expression and insulin sensitivity independent of changes in body weight in female obese mice, Nutr. Diabetes, 2, 10.1038/nutd.2012.4